Kestra Medical Technologies (NASDAQ:KMTS) Insider Timothy Moran Sells 4,117 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Timothy Moran sold 4,117 shares of the business’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $22.77, for a total value of $93,744.09. Following the completion of the sale, the insider owned 77,484 shares in the company, valued at $1,764,310.68. This represents a 5.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Price Performance

Shares of NASDAQ:KMTS opened at $23.99 on Tuesday. The firm has a market capitalization of $1.41 billion, a PE ratio of -9.91 and a beta of 0.58. The company has a quick ratio of 4.41, a current ratio of 4.41 and a debt-to-equity ratio of 0.16. The company has a 50-day moving average price of $22.62 and a two-hundred day moving average price of $22.48. Kestra Medical Technologies, Ltd. has a twelve month low of $14.10 and a twelve month high of $30.00.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The business had revenue of $28.64 million during the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. Equities analysts forecast that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

Analyst Ratings Changes

KMTS has been the topic of several recent research reports. Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a research report on Wednesday, July 15th. The Goldman Sachs Group reduced their price target on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Wall Street Zen cut Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Weiss Ratings downgraded Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 16th. Finally, Oppenheimer began coverage on Kestra Medical Technologies in a report on Tuesday, July 21st. They set a “market perform” rating for the company. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $27.83.

Institutional Trading of Kestra Medical Technologies

Several institutional investors and hedge funds have recently bought and sold shares of the company. Millennium Management LLC bought a new position in Kestra Medical Technologies in the 1st quarter valued at $11,036,000. Woodline Partners LP bought a new position in shares of Kestra Medical Technologies in the first quarter worth $2,510,000. Jane Street Group LLC bought a new position in shares of Kestra Medical Technologies in the first quarter worth $756,000. Geode Capital Management LLC raised its position in shares of Kestra Medical Technologies by 718.5% in the second quarter. Geode Capital Management LLC now owns 325,326 shares of the company’s stock worth $5,395,000 after buying an additional 285,579 shares in the last quarter. Finally, JPMorgan Chase & Co. bought a new stake in Kestra Medical Technologies during the second quarter valued at $256,000.

Kestra Medical Technologies News Summary

Here are the key news stories impacting Kestra Medical Technologies this week:

• Neutral Sentiment: Multiple executives, including CFO Vaseem Mahboob and insiders Brian Daniel Webster, Traci S. Umberger, Alfred J. Ford Jr. and Timothy P. Moran, sold shares between July 30 and August 3. The transactions totaled approximately 103,000 shares and more than $2.3 million at prices near $22.60–$23.92. Each filing states that the sales were made to cover tax-withholding obligations tied to vested equity awards, rather than for discretionary investment purposes. SEC insider transaction filings
• Negative Sentiment: The breadth of the selling—including transactions by the CFO and several other insiders—could weigh on sentiment because it reduces management ownership and creates a perception of insider selling pressure. However, the relatively small percentage reductions in most positions and the disclosed tax-related purpose make the signal less bearish than open-market sales based on an expectation of weaker business performance.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.